In conclusion, our study provides the first evidence of the performance of the GALAD score for early-stage HCC detection in Latin American patients, and we show that further optimization of the GALAD score is required, especially for detecting small tumors or tumors with low AFP levels. The gene discussed is AFP; the disease is hepatocellular carcinoma.